TARA News and Press, ArTara Therapeutics Inc.

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grant of inducement non-qualified stock options to purchase an aggregate of 118,40...

2024-05-23 16:47:49 ET Gainers: Ross Stores ( ROST ) +6% . Frontier Group Holdings ( ULCC ) +4% . Caribou Biosciences ( CRBU ) +4% . Absci Corporation ( ABSI ) +3% . Protara Therapeutics ( TARA ) +3% . Losers: Domo ( DO...

NEW YORK, May 21, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 5t...

2024-05-02 08:49:35 ET More on Protara Therapeutics Protara: A Bombed Out Biotech With A Very Positive Skew Protara Therapeutics jumps 23% on $45M oversubscribed private financing Seeking Alpha’s Quant Rating on Protara Therapeutics Historical earnings...

Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 Reached alignment with FDA on registrational p...

2024-04-22 10:01:12 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Tech advances are catalyzing the Health Care sector with improved ...

2024-04-05 09:17:42 ET More on Protara Therapeutics Protara: A Bombed Out Biotech With A Very Positive Skew Seeking Alpha’s Quant Rating on Protara Therapeutics Historical earnings data for Protara Therapeutics Financial information for Protara Therape...

2024-04-05 09:03:21 ET DENVER, Colo., Apr 05, 2024 ( 247marketnews.com )- Protara Therapeutics, Inc. (NASDAQ: TARA ) published three announcements today, including positive data from three-month evaluable carcinoma in situ (CIS) patients treated across its ongoing clinical prog...

NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has entered into a subscription agreement for the sale of an aggregate o...

New development pathway significantly expands addressable patient population for IV Choline Chloride IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S. Approximately 80% of PN patients are cho...